In-Vivo Assessment of Immunomodulatory Activity and Acute Toxicity of a Tulsi–Ginger Polyherbal Formulation

The immune system is an intricate defense network that protects the body from infectious agents, abnormal cells, and foreign substances. The growing prevalence of immune-compromised conditions, emerging infectious diseases, and antibiotic resistance has renewed interest in natural immunomodulators. Traditional herbal medicines offer a wide spectrum of bioactive phytochemicals that act through multiple mechanisms to enhance both innate and adaptive immunity [1]. Among these, Ayurvedic herbs such as Tulsi (Ocimum sanctum) and Ginger (Zingiber officinale) have been extensively documented for their therapeutic properties. Tulsi is known for its adaptogenic, antioxidant, anti-inflammatory, and immunomodulatory activities, while Ginger exhibits potent anti-inflammatory, antimicrobial, and immune-enhancing properties [2,3]. Both are widely consumed in India in traditional preparations and dietary supplements, making them excellent candidates for polyherbal formulations aimed at immune support.Polyherbal formulations  where multiple plant ingredients are combined  are believed to produce synergistic effects through the interaction of diverse phytoconstituents. Such formulations may enhance efficacy, broaden the spectrum of activity, and reduce potential toxicity compared to single-herb preparations [4]. This review summarizes current knowledge on Tulsi and Ginger in the context of immunomodulation, focusing on in-vivo studies, toxicity profiles, and regulatory considerations.

2. Pharmacological Significance of Tulsi and Ginger

2.1 Tulsi (Ocimum sanctum)

Tulsi, often referred to as "Holy Basil," is revered in Ayurveda as a Rasayana herb with rejuvenating and immune-boosting effects. It contains a rich array of phytoconstituents, including eugenol, ursolic acid, rosmarinic acid, and flavonoids, which contribute to its pharmacological profile [5]. Studies have shown that Tulsi modulates immune function by stimulating lymphocyte proliferation, enhancing macrophage activity, and upregulating cytokine production [6]. It also exhibits strong antioxidant properties, reducing oxidative stress  a key factor in immune dysregulation [7].

2.2 Ginger (Zingiber officinale)

Ginger rhizomes are widely used for their culinary and medicinal properties. The main bioactive compounds, such as gingerols and shogaols, possess immunomodulatory, anti-inflammatory, and antimicrobial actions [8]. Ginger has been reported to enhance the phagocytic activity of macrophages, modulate T and B cell responses, and influence cytokine production [9]. Its antioxidant activity further supports immune function by neutralizing free radicals and preventing oxidative damage [10].Table 1 presents a comparative overview of the key pharmacological properties of Tulsi and Ginger, highlighting their complementary phytochemical profiles and mechanisms of immunomodulation.

Table 1. Comparative Pharmacological Properties of Tulsi and Ginger

3. Polyherbal Formulations and Immunomodulation

The Ayurvedic principle of polyherbalism is based on the concept that combining multiple herbs in a single formulation produces a synergistic enhancement of therapeutic efficacy, where the overall effect is greater than the sum of the individual components [11]. This principle, deeply rooted in traditional Indian medicine, aims not only to maximize therapeutic efficacy but also to minimize toxicity by balancing the pharmacological actions of different herbs [12]. Tulsi–Ginger formulations exemplify this philosophy and are commonly prepared in diverse dosage forms such as decoctions, powders, tablets, and syrups, making them accessible and adaptable for both preventive and therapeutic use [13].The phytoconstituents of Tulsi, including eugenol, ursolic acid, and flavonoids, act through immunomodulatory, antioxidant, and anti-inflammatory pathways, whereas Ginger contributes active compounds such as gingerols and shogaols that enhance phagocytic activity, modulate cytokine production, and provide antimicrobial protection [5,8,9,10]. When combined, these bioactive compounds interact synergistically to potentiate immune responses, improve the bioavailability of active ingredients, and create a balanced pharmacological profile that supports both innate and adaptive immunity [12,14].Experimental evidence supports this rationale: several in-vivo studies have demonstrated that Tulsi–Ginger polyherbal formulations significantly enhance antibody titers, improve delayed-type hypersensitivity (DTH) responses, and increase macrophage activity compared to individual extracts, indicating stimulation of both humoral and cell-mediated immunity [15,16]. Mechanistic insights suggest that this synergy arises from complementary actions Tulsi primarily modulates cytokine networks and reduces oxidative stress, while Ginger enhances innate immune cell activity and regulates inflammatory mediators [13,15]. Together, they create a dual-action system that strengthens host defense mechanisms while maintaining immune homeostasis.Figure 1 illustrates the synergistic immunomodulatory mechanism by which the Tulsi–Ginger polyherbal combination activates both arms of the immune system through complementary phytoconstituents and improved bioavailability.

Figure 1. Synergistic immunomodulatory mechanism of Tulsi (Ocimum sanctum) and Ginger (Zingiber officinale) polyherbal formulation. The combination enhances both humoral and cell-mediated immunity through complementary phytoconstituents, improved bioavailability, and balanced pharmacological actions.

Beyond their immunostimulant effects, polyherbal formulations also reduce the risk of adverse reactions associated with high doses of single-herb extracts, as the presence of multiple constituents allows dose-sparing and pharmacodynamic balancing [11,17]. From a translational perspective, Tulsi–Ginger formulations hold promise as prophylactic immune boosters, particularly in populations vulnerable to infections, immune suppression, or oxidative stress-related disorders [18]. Their affordability, cultural acceptance, and favorable safety profile further enhance their potential as supportive agents in preventive healthcare. Moreover, the concept of polyherbalism aligns with modern pharmacological strategies that emphasize multi-targeted approaches for complex diseases, suggesting that traditional Ayurvedic wisdom may provide valuable frameworks for developing next-generation immunotherapeutics [19,20].

4. In-Vivo Immunostimulatory Studies

In-vivo studies provide critical insights into how herbal formulations influence immune responses under physiological conditions, capturing the complex interactions between immune cells, signaling molecules, and organ systems [14]. Tulsi (Ocimum sanctum) extract has been widely reported to enhance both humoral and cell-mediated immunity, with studies showing increased antibody titers, stimulation of T-lymphocyte proliferation, and modulation of Th1/Th2 cytokine pathways [15,16]. Similarly, Ginger (Zingiber officinale) supplementation in rodent models has demonstrated significant improvements in innate and adaptive immune responses, including enhanced macrophage phagocytic activity, increased natural killer (NK) cell cytotoxicity, and elevated antibody production, along with a marked reduction in pro-inflammatory mediators such as TNF-α and IL-6 [9,10,17].Table 2 summarizes key in-vivo immunostimulatory studies conducted with individual Tulsi or Ginger extracts and Tulsi–Ginger polyherbal formulations, illustrating the range of immune parameters investigated and the consistent pattern of immune enhancement observed across study models.

Table 2. Summary of In-Vivo Immunostimulatory Studies

When combined in polyherbal formulations, Tulsi and Ginger exhibit synergistic effects that surpass the activity of either herb alone. Rodent studies have revealed substantial increases in delayed-type hypersensitivity (DTH) responses, hemagglutination antibody titers, and splenic lymphocyte proliferation in groups treated with Tulsi–Ginger formulations compared to individual extracts and controls, suggesting stimulation of both humoral and cell-mediated immunity [13,18]. Mechanistic investigations further indicate that these immunostimulatory effects are mediated through enhanced antioxidant defenses such as upregulation of superoxide dismutase (SOD), catalase, and glutathione peroxidase along with cytokine regulation that maintains a balanced Th1/Th2 response [19]. Histopathological analyses of immune organs such as the spleen and thymus show improved structural integrity and increased lymphoid proliferation in animals treated with Tulsi–Ginger combinations, reinforcing the evidence of immunoenhancement [18,20]. Figure 2 presents the proposed in-vivo immunostimulatory pathway of the Tulsi–Ginger polyherbal formulation, from oral absorption through activation of immune organs to downstream enhancement of humoral and cell-mediated immunity.

Figure 2. Synergistic immunostimulatory pathway of Tulsi (Ocimum sanctum) and Ginger (Zingiber officinale) polyherbal formulation. Oral administration leads to absorption and distribution of phytoconstituents, uptake by immune organs, activation of T and B lymphocytes, modulation of cytokine networks, and ultimately enhanced humoral and cell-mediated immunity with reduced oxidative stress.

5. Toxicity Studies and Safety Evaluation

Safety evaluation is a cornerstone in the development of herbal formulations intended for human use, ensuring that therapeutic benefits are not overshadowed by potential adverse effects [17]. Acute toxicity studies conducted in rodents, in accordance with OECD Guidelines 423 and 425, consistently report no mortality or significant behavioral changes following oral administration of Tulsi (Ocimum sanctum) and Ginger (Zingiber officinale) extracts at doses far exceeding traditional therapeutic ranges [21,23]. Hematological and biochemical parameters, including red and white blood cell counts, hemoglobin levels, liver enzymes (ALT, AST), and kidney function markers (BUN, creatinine), generally remain within normal physiological limits, while necropsy and histopathological examinations reveal no pathological abnormalities in vital organs such as the liver, kidney, spleen, or heart [18,22].Sub-chronic and chronic toxicity studies further support a favorable safety profile, demonstrating that long-term administration of Tulsi and Ginger at therapeutic doses does not induce cumulative toxicity or organ damage [19,21]. Importantly, polyherbal combinations of Tulsi and Ginger often exhibit reduced toxicity compared to high-dose single extracts, a phenomenon attributed to the balancing effects of multiple phytoconstituents that mitigate potential adverse reactions through pharmacodynamic harmonization [12,20]. This dose-sparing and toxicity-reducing effect aligns with the Ayurvedic principle of Yukti (rational combination), where herbs are intentionally combined to enhance efficacy while minimizing risk [11].Table 3 provides a consolidated summary of toxicity and safety evaluation findings for Tulsi–Ginger formulations across multiple parameters including hematological, biochemical, histopathological, and genotoxicity assessments.

Table 3. Toxicity and Safety Evaluation of Tulsi–Ginger Formulations

5.1 Acute Toxicity Study of the Polyherbal Formulation

Acute toxicity studies form an integral part of the preclinical safety assessment of herbal and polyherbal formulations. These studies identify the immediate toxic effects and establish the dose range and lethal dose (LD??) for safe therapeutic use. In Tulsi–Ginger polyherbal formulations, acute toxicity testing is particularly necessary because the interaction of multiple plant constituents may alter the pharmacodynamic profile compared to single-herb preparations. Although both Tulsi and Ginger are recognized as safe individually, their combination must be evaluated to ensure that synergistic or cumulative effects do not introduce new toxicities. Acute toxicity studies are performed in accordance with OECD Guidelines 423 and 425 and are mandated by AYUSH for all Ayurvedic formulations intended for clinical use.The study typically employs healthy adult female mice or rats due to their higher sensitivity to toxic agents. The test formulation is administered orally (to mimic human use) in graded doses of 300, 1000, 2000, and up to 5000 mg/kg body weight. After dosing, animals are continuously monitored for 4 hours and then periodically for 14 days for signs of toxicity such as tremors, convulsions, salivation, drowsiness, or respiratory distress. Body weight, food and water intake, and overall appearance are recorded. At the end of the observation period, blood samples are collected for hematological and biochemical analyses, evaluating red and white blood cell counts, hemoglobin, liver enzymes (ALT, AST), and renal markers (BUN, creatinine). Subsequently, gross necropsy and histopathological examination of the liver, kidney, spleen, heart, and lungs are performed to detect any tissue damage or pathological abnormalities.Figure 3 illustrates the standard acute toxicity study design used in rodent models, demonstrating the dosing, observation, and endpoint assessment timeline mandated by OECD Guidelines 423/425 for preclinical evaluation of herbal formulations.

Figure 3. Acute oral toxicity study design for the Tulsi–Ginger polyherbal formulation in rodent models, following OECD Guidelines 423/425 and AYUSH preclinical evaluation standards. The schematic outlines animal selection, graded dose administration (300–5000 mg/kg BW, oral), acute and 14-day monitoring, and endpoint assessments including hematology, serum biochemistry, and histopathology. Safety outcome: NOAEL ≥ 2000 mg/kg; GHS Category 5 (Non-toxic).

Results from multiple studies indicate that Tulsi–Ginger polyherbal formulations show no mortality or abnormal behavior up to the highest tested dose (2000 mg/kg or more). Hematological and biochemical parameters remain within normal physiological limits, and histopathology reveals no morphological damage in vital organs. The No Observed Adverse Effect Level (NOAEL) is thus established at a high dose, confirming a wide margin of safety. The findings support classification of the formulation as non-toxic (GHS Category 5) and validate its safety for long-term use. These outcomes underscore that the Tulsi–Ginger polyherbal formulation is well-tolerated and suitable for further sub-chronic, chronic, and clinical evaluations [20–23].

6. Regulatory Perspectives and Standardization

Regulatory frameworks governing herbal medicines vary significantly across countries, yet share common goals of ensuring safety, efficacy, and quality of plant-based products intended for human consumption. In India, the Ministry of AYUSH in conjunction with the Central Drugs Standard Control Organization (CDSCO) mandates Good Manufacturing Practice (GMP) compliance, strict adherence to Schedule E drug listings, and preclinical toxicity data (including OECD 423/425 acute toxicity studies) prior to clinical use of Ayurvedic formulations [24]. These requirements align the Indian regulatory framework with international standards while respecting traditional knowledge systems.Table 4 compares the major global regulatory frameworks applicable to polyherbal immunomodulatory formulations such as Tulsi–Ginger preparations, highlighting jurisdiction-specific requirements for safety documentation and market authorization.

Table 4. Regulatory Frameworks for Polyherbal Formulations Across Major Jurisdictions

At the international level, the World Health Organization (WHO) has published comprehensive guidelines for the quality control, phytochemical profiling, and safety assessment of herbal medicines, emphasizing the need for standardized extraction processes, contaminant testing, and documentation of traditional use [24,25]. In the European Union, the European Medicines Agency (EMA) accepts bibliographic and mixed marketing authorization applications for herbal medicinal products, requiring a complete non-clinical safety dossier that includes reproductive and developmental toxicity data [26]. In the United States, polyherbal products are regulated under the Dietary Supplement Health and Education Act (DSHEA, 1994), with novel extracts requiring New Dietary Ingredient (NDI) notifications to the FDA [24].Standardization of Tulsi–Ginger formulations remains a critical challenge for global regulatory acceptance. Key quality parameters include quantification of marker compounds (eugenol for Tulsi; gingerols and shogaols for Ginger) using validated HPLC or LC-MS methods, microbiological testing, heavy metal screening, and stability studies across temperature and humidity conditions. Adherence to these standards not only facilitates regulatory approval but also ensures consistent therapeutic outcomes and consumer safety across production batches.Table 5 summarizes validated analytical methods and quality control benchmarks recommended for the standardization of Tulsi–Ginger polyherbal formulations, supporting batch reproducibility and regulatory compliance. Figure 4 depicts the complete phytochemical standardization and quality control workflow from raw material authentication through to final release testing.

Table 5. Recommended analytical methods and acceptance criteria for phytochemical standardization and quality control of Tulsi–Ginger polyherbal formulations. TAMC = Total Aerobic Microbial Count; NLT = Not Less Than; RSD = Relative Standard Deviation; LOQ = Limit of Quantification.

Figure 4. Phytochemical standardization and quality control workflow for the Tulsi–Ginger polyherbal formulation. The pipeline integrates botanical authentication, HPLC/LC-MS marker quantification, contaminant screening (heavy metals, pesticides, aflatoxins), microbial limit testing, and accelerated stability studies to ensure GMP-compliant, batch-reproducible production in accordance with AYUSH, WHO, and EMA guidelines.